Lilly Reups With Nimbus in $1.3B Oral Obesity Deal
Eli Lilly has signed a new collaboration with Nimbus Therapeutics worth up to $1.3B to develop a novel oral obesity drug.
News
NeuroPulse Daily January 7, 2026
VB Spine Completes Acquisition of Stryker’s Cestas Manufacturing Facility Pulse: Anavex Receives Constructive FDA Feedback on Alzheimer’s Disease Program Pulse: Newleos Therapeutics Doses First Patient in Phase 2 SOAR Study for Social Anxiety Disorder Pulse: Lysoway Therapeutics Advances LW-1017 to Phase I Readiness in Neurodegeneration Pulse: LoQus23 Nominates LQT-23 as First-in-Class Oral Drug Candidate for … Read more
Ikarovec Eyes $1B Deal to Move Eye Gene Therapy In-Office
UK biotech Ikarovec teams with VectorBuilder on eye gene delivery.
NICE Clears MS Treatment Option Suitable During Pregnancy
NICE backs natalizumab for highly active relapsing MS.
NICE Backs Age-Based Blood Test to Spot Ovarian Cancer
NICE proposes age-based CA125 testing to improve early diagnosis.
Sanofi, Earendil Lab ink $2.5B deal for bispecific antibody
Sanofi has entered a strategic collaboration with Earendil Labs worth up to $2.56B to discover bispecific antibodies.
AbbVie Bets $1.2B on Zelgen’s DLL3 Trispecific
AbbVie has licensed ex-China rights to Zelgen’s DLL3 trispecific T-cell engager ZG006 in a deal worth up to $1.2B.
Germany Updates Meningococcal, Shingles Vaccine Policy for 2026
Germany adopts new STIKO vaccination recommendations, shifting meningococcal protection to adolescents and expanding shingles eligibility for high-risk adults starting in 2026.
EU Finalizes Landmark Pharma Reform to Reset Access and Incentives
The EU reaches a landmark deal on pharmaceutical reform, reshaping regulatory exclusivity, supply obligations, generic entry, and incentives for priority antibiotics.
BioMarin to Acquire Amicus for $4.8B in Rare Disease Deal
BioMarin will acquire Amicus Therapeutics for $4.8B in cash, adding Galafold and Pombiliti + Opfolda and accelerating rare-disease revenue growth.